Go to http://www.manageyourtreatment.org for more information.
Cancer has touched the lives of all of us. Each year, it takes the lives of more than half a million Americans and seven million people worldwide.
Cynthia Nixon and Edie Falco will appear in this PSA to encourage cancer patients to win back some control in their lives by managing their treatment. In their role as the campaign ambassadors, Falco and Nixon appear to encourage people to better understand their options and provide support for managing their care.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
While the government claims to provide pricing for drugs and procedures, those listings only highlight what Medicare and Medicaid are willing to reimburse, not what those services actually cost. Hospitals, doctors and insurance companies provide patients with an itemized bill for care – but only AFTER the fact. The Healthcare Transparency Index, issued today by change:healthcare, is the first to provide healthcare consumers with ongoing trends data about actual healthcare costs – offering insight into critical opportunities for cost savings.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/changehealthcare/46792/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or ‘bird flu,’ even when given late in the course of illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/outcome/46648/
Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients.
Spine surgery has advanced significantly over the past decade, allowing for more reliable outcomes, less surgical morbidity and quicker recovery. Dr Steven Cyr of the Orthopaedic & Spine Institute in San Antonio (http://www.saspine.com) offers some of the country’s most advanced training, compassionate care and individualized treatment options to help eliminate back and neck pain and improve his patients’ quality of life.
To view MultiMedia News Release, go to http://multivu.prnewswire.com/mnr/closeuptvnews/46410/
People in the UK, who currently have significantly poorer access to cancer medicines compared to those in Europei, could soon be gaining access to life saving cancer treatments which are currently not available on the NHS, with the launch of the Cancer Drugs Fund. The interim funding of £50 million for cancer drugs made available today is ahead of the introduction of a longer term Cancer Drugs Fund of £600 million from 2011-2014.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/wishingwall/46284/
After a successful pilot program in October 2009, Cancer Treatment Centers of America (CTCA) is introducing an innovative approach to cancer treatment this July at each of its four hospitals in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Called “Patient Empowered CareSM,” this advancement in the patient treatment delivery process offers patients an average of between two and three hours with a dedicated team of specialized oncology physicians and clinicians.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancercenter/44523/
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Surmang Foundation has operated a primary care clinic in a remote, poor region of Western China, in partnership with the Chinese Government, Qinghai Province, and Yushu Prefecture, since 1992. The Core Project has treated over 60,000 patients for free, including medicine, since the clinic building was completed in 1996. Its focus is on the maternal and child mortality/morbidity rates of the region, among the highest in the world. It supports two local ethnic Tibetan doctors, Phuntsok Dongdrup and Sonam Drogha.
In our catchment area, the average annual income is about $50. Surmang Foundation’s remote site is a test case and a model for all of rural China, because impoverished nomadic Tibetans manifest in the extreme, most rural health and poverty problems. In cooperation with the Chinese Government and several hospitals, Surmang Foundation is currently expanding its mission to address the lack of access to basic services among the 28 million impoverished residents of rural, Western China and the lack of capacity of the local medical providers.
The pilot project will create a network of remote providers for IT-based distance medical education and remote diagnosis and referral. The pilot began in 2005 with the promulgation of an archive of all Tibetan and Chinese language health promotion materials and continued in 2006 with the installation of a satellite dish at the Surmang campus.
A part of that is the Community Health Worker Project funded by an AmCham grant in Spring 2005.
Surmang Foundation has partnered with the Soong Ching-ling Foundation since November 2005.
